SCHEMBL17295392

SCHEMBL17295392

O=C1C(=Cc2ccc3[nH]ccc3c2)SC(=Nc2ccccc2)N1CCCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 7/20 0.51
▸ ACP1 P24666 6/20 0.51
▸ FAAH O00519 1/20 0.49
▸ LMNA P02545 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ S1PR1 P21453 1/20 0.48
▸ S1PR3 Q99500 1/20 0.48
▸ CA9 Q16790 8/20 0.47
▸ CA2 P00918 1/20 0.47
▸ PTPN2 P17706 4/20 0.46
▸ AKR1B1 P15121 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17295389 1.00 PTPN1 (0.51) PTPN1ACP1FAAHLMNAHPGD
SCHEMBL17302191 0.90 FAAH (0.57) PTPN1ACP1FAAHLMNAHPGD
SCHEMBL17295414 0.89 ALDH1A1 (0.51) PTPN1ACP1FAAHLMNAHPGD
SCHEMBL17295415 0.89 ALDH1A1 (0.51) PTPN1ACP1FAAHLMNAHPGD
SCHEMBL17302227 0.89 PTPN1 (0.64) PTPN1ACP1CA9CA2PTPN2
SCHEMBL17295441 0.84 LMNA (0.49) PTPN1ACP1FAAHLMNAHPGD
SCHEMBL17295442 0.84 LMNA (0.49) PTPN1ACP1FAAHLMNAHPGD
SCHEMBL17295269 0.83 MAPT (0.52) PTPN1ACP1FAAHLMNAHPGD
SCHEMBL17295268 0.83 MAPT (0.52) PTPN1ACP1FAAHLMNAHPGD
SCHEMBL29726504 0.83 MAPT (0.52) PTPN1ACP1FAAHLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3148990-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION Universität Bern (CH) 2017-04-05 — — EP disclosed
WO-2015181337-A1 THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION Universität Bern (CH) 2015-12-03 — — WO disclosed
Send feedback